Needham upgrades Rocket Pharmaceuticals to Buy after FDA alignment
Needham upgraded Rocket Pharmaceuticals (RCKT) to ‘Buy’ from… after the company aligned with the U.S. FDA on a pivotal study for its experimental genetic disease therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Needham upgrades Rocket Pharmaceuticals to Buy
Needham upgraded Rocket Pharmaceuticals to Buy from Hold, according to ratings actions cited by Benzinga.
Needham upgrades Rocket Pharmaceuticals to Buy, sets $9 target
Needham upgraded Rocket Pharmaceuticals to Buy and set a $9.00 price target, implying 163.9% upside versus the Sep 15 close of $3.41.